Caricamento...
BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors
The bromodomain and extra-terminal domain (BET) proteins are promising therapeutic targets to treat refractory solid tumors; however, inherent resistance remains a major challenge in the clinic. Recently, the emerging role of the oncoprotein B cell lymphoma 6 (BCL6) in tumorigenesis and stress respo...
Salvato in:
| Pubblicato in: | J Clin Invest |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society for Clinical Investigation
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7773368/ https://ncbi.nlm.nih.gov/pubmed/33393503 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI133090 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|